This randomized, double-blind, single-site phase II 2-arm study will investigate the safety and preliminary efficacy of MDMA-assisted therapy compared with low dose d-amphetamine-assisted therapy on the severity of PTSD symptoms in participants aged 18 years and older with PTSD of at least moderate severity.
At Screening, meet DSM-5 criteria for current PTSD with a symptom duration of at least 6 months.
Fluent in speaking and reading the predominantly used or recognized language of the study site (English).
Must be a veteran enrolled at a VA Healthcare Center in the Greater Los Angeles area.
Able to swallow pills.
Are not able to give adequate informed consent.
Have evidence or history of significant medical or psychiatric disorders.
Are abusing illegal drugs.
Unable or unwilling to safely taper off prohibited psychiatric medication.
Stephen Robert Marder
Lead sponsor
VA Greater Los Angeles Healthcare System
Sponsor institution